ClinicalTrials.gg
CompletedNCT02253901Updated Oct 1, 2014

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

A Phase 1 interventional study of BILR 355 BS and Ritonavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

Study to determine the pharmacokinetic effect of BILR 355 + ritonavir® on TRUVADA and TRUVADA on BILR 355

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females who meet the inclusion/exclusion criteria; females must not be pregnant or nursing, and must agree to use a double-barrier method of (condoms or diaphragm, plus spermicide) throughout the trial (alone or in addition to other methods of birth control such as oral contraceptives)
  • Age ≥18 and \<60 years
  • (BMI) ≥18.5 and BMI ≤29.9 kg/m2
  • Ability to give signed and dated written prior to admission to the study in accordance with good clinical practice (GCP) and the local regulations

Exclusion criteria

Exclusion Criteria:

  • Current (symptomatic within the last 30 days) and medically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Currently active (symptomatic within the last 30 days) diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (>24 hours) within one month prior to administration of study drug or during the trial (review with clinical monitor if questionable)
  • Use of drugs within 10 days prior to administration or during the trial, which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation (review with clinical monitor if questionable)
  • Participation in another trial with an drug within one month prior to administration or during the trial
  • Current smoker
  • Alcohol (more than 60 g/day) or drug abuse (positive urine test for illicit prescription or non-prescription drugs or drugs of abuse)
  • Recent blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
  • Excessive physical activities (within 1 week prior to study drug administration or during the trial)
  • Any laboratory value outside the normal reference range that is of clinical relevance at screening, according to the judgment of the investigator
  • Inability to comply with dietary regimen required by the protocol
  • Chronic or relevant acute infections
  • Infected with or viruses (defined as either being hepatitis B surface antigen, or hepatitis C antibody positive)
  • -1 infected as defined by a positive HIV ELISA test
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    TRUVADA with BILR 355 BS and ritonavir

    Drug: BILR 355 BS · Drug: Ritonavir · Drug: TRUVADA

  • Active comparator
    BILR 355 BS in combination with ritonavir

    Drug: BILR 355 BS · Drug: Ritonavir

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from 0 to 24 hours at steady state of the analyte in plasma (AUC0-24h,ss)

    Time frame: up to 24 h after treatment

Secondary outcomes

  1. Apparent clearance of the analyte in plasma following extravascular administration at steady state (CL/F,ss)

    Time frame: up to day 18 after start of treatment

  2. Time from dosing to the maximum concentration of the analyte in plasma at steady state (tmax,ss)

    Time frame: up to day 18 after start of treatment

  3. Measured concentration of the analyte in plasma 24 hours post last dose at steady state (Cp24h, ss)

    Time frame: up to 24 h after treatment

  4. Terminal half-life of of the analyte in plasma in the plasma at steady state (t1/2, ss)

    Time frame: up to day 18 after start of treatment

  5. Apparent volume of distribution of of the analyte in plasma during the terminal phase λz at steady state following an extravascular dose (Vz/F,ss)

    Time frame: up to day 18 after start of treatment

  6. Area under the concentration-time curve from 0 to 24 hours of ritonavir in plasma (AUC0-24h)

    Time frame: up to 24 h after treatment

  7. Maximum measured concentration of ritonavir in plasma (Cmax)

    Time frame: up to 24 h after treatment

  8. Number of subjects with clinically relevant changes in clinical laboratory tests

    Time frame: up to day 28 after start of treatment

  9. Number of subjects with clinically relevant changes in vital signs (blood pressure, pulse rate)

    Time frame: up to day 28 after start of treatment

  10. Number of subjects with adverse events

    Time frame: Up to 7 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005 and a primary completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 1, 2014
Start
Mar 2005
Primary completionActual
May 2005
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02253901
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Mar 2005
Primary completion
May 2005
Last update
Oct 1, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 5,11-dihydro-11-ethyl-5-methyl-8-(2-(1-oxido-4-quinolinyl)ethyl)-6H-dipyrido(3,2-B,2',3'-E)(1,4)diazepin-6-one · Bilr 355 · Ritonavir

Start the discussion